Bachet, Jean-Baptiste

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 7,810

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 2,874

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 2,229

Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 673

Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features

Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., Quertinmont, E., Svrcek, M., Elarouci, N., Iovanna, J., et al. (2018) · Gastroenterology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 563